N

Nephrology Associates of Northern Virginia | Fairfax, VA

Research site

(Unclaimed)

Location

13135 Lee Jackson Memorial Highway Suite #135, Fairfax, Virginia, United States of America

Site insights

Top conditions

Top treatments

Bardoxolone Methyl

Sitagliptin

Vildagliptin

Lixivaptan

Atrasentan

Finerenone

RO7434656

Lanthanum Carbonate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling

Primary Membranous Nephropathy

Drug: Rituximab

Drug: SNP-ACTH (1-39) Gel

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in...

Enrolling

Primary IgA Nephropathy

Drug: RO7434656

Drug: Placebo

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: Placebo

Drug: Atrasentan